Loading...

Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. Median survival for metastatic patients is six to nine months and survivors beyond one year are exceptional. Pancreatic cancer is resistant to conventional chemotherapy and is often diagnosed at advanced stages. However, immuno...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cureus
Main Authors: Costa Neves, Mafalda, Giakoustidis, Alex, Stamp, Gordon, Gaya, Andy, Mudan, Satvinder
Format: Artigo
Sprog:Inglês
Udgivet: Cureus 2015
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4731256/
https://ncbi.nlm.nih.gov/pubmed/26870619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.435
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!